HUNTSVILLE — HealthŌme, a genomics-based, health navigation company, has acquired Kailos Genetics, a genetic testing laboratory and supplier of clinical grade laboratory reagents for next-generation genomic sequencing.
Both companies are on the HudsonAlpha Institute for Biotechnology campus in Cummings Research Park.
“Bringing together two HudsonAlpha associate companies to form a leading healthcare management company is an exciting step forward in advancing healthcare solutions,” said Jim Hudson, a founder of HudsonAlpha. “This merger has the potential to drive innovation, improve the patient experience, and make significant contributions to the field of genomics and personalized medicine.”
With the acquisition, healthŌme positions itself at the forefront of healthcare innovation, leveraging Kailos Genetics’ expertise to expand its testing capabilities and creating an unprecedented precision health management company serving the insurance and life science industries, according to the press release.
“Our merger with Kailos Genetics builds upon the partnership we began with Kailos when healthŌme was founded and is rooted in our shared vision and values,” said Darren Rowe, CEO at healthŌme. “This merger creates an optimal path to improve health, enhance long-term company value, and provides opportunities to cultivate market-leading solutions for the life insurance industry.
“We wholeheartedly welcome the exceptionally talented Kailos team to the healthŌme family. Together, we are poised to make a profound impact on improving and extending healthy life through the alternative funding channels of life and critical illness insurance.”
Kailos Genetics and healthŌme have a shared vision to create an elevated health management experience where individuals are empowered to make informed decisions by creating a personalized healthcare strategy supported of experts in the field of genomics, genetic counseling, and precision medicine, said the press release.
The acquisition provides healthŌme access to advanced technology and research including Kailos’ state-of-the-art CLIA-certified and CAP-accredited laboratory facilities, patented and licensed technology, and robust research capabilities.
It enhances both company’s service portfolio and enables the development of a broader range of clinical testing options, ensuring individuals, physicians, hospitals, and healthcare providers, as well as healthŌme’s life insurance clients, have access to cutting-edge testing solutions for accurate diagnosis and personalized health management plans.
It also expands the diverse team of experts in the field of genomics, clinical diagnostics development, and clinical laboratory management for healthŌme.
Currently, healthŌme provides its customers with hereditary cancer risk screening and pharmacogenetic testing through Kailos Genetics. As a wholly owned subsidiary of healthŌme, Kailos Genetics will continue to provide its full range of services and reagents to the marketplace, in addition to the services currently provided to healthŌme.
The acquisition extends and strengthens healthŌme’s supply chain and heightens their ability to harness the rapidly progressing field of genomics and precision medicine.
Through access to advanced genomics and precision medicine, healthŌme provides its policyholders with high-value, practical, precision health management resources that support longer and healthier life.
With the acquisition, Kailos Genetics, in turn, diversifies its laboratory services business model beyond the confines of traditional healthcare reimbursement and payer systems.
The acquisition also opens doors to new markets through the life and critical insurance industry distribution channels, where healthŌme products are prominently sold.
By tapping into these expansive distribution channels, Kailos Genetics gains wider market reach for its testing services, unlocking new growth opportunities and establishing a solid foundation for future success.
Brian Pollock, founder and CEO of Kailos Genetics, is now president of Kailos Genetics.
“Kailos is excited to become part of the healthŌme family, bringing our expertise in sequencing-based solutions to deliver unparalleled value to healthŌme clients while upholding the exceptional service our existing customers expect,” he said.
The integration of both companies begins immediately with a focus on maintaining uninterrupted services for existing customers while continuing to explore opportunities for expanding service offerings.
Don’t miss out! Subscribe to our email newsletter to have all our smart stories delivered to your inbox.
